Increased Early Postprandial Glucagon Concentrations in Humans With Newly Diagnosed Type 2 Diabetes and Steatotic Liver Disease
Diabetes Care · 2026
DOI: 10.2337/dc25-3077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, 2026. Verfasst von Maximilian Huttasch und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon, Fatty Liver. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: German Diabetes Society, German Federal Ministry of Health (BMG), Ministry of Culture and Science of the State of North Rhine-Westphalia.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE Glucagon-based polyagonists improve metabolic dysfunction–associated steatotic liver disease (MASLD), which could result from glucagon-stimulated hepatic lipid oxidation. Nevertheless, people with long-standing type 2 diabetes (T2D) exhibit a paradoxical rise in both hepatic lipid content (HLC) and glucagon levels, which has been related to disturbed hepatic metabolism generating glucagonotropic metabolites such as amino acids and nonesterified fatty acids (NEFAs). We examined these relationships in individuals with normal glucose tolerance (NGT) and newly diagnosed T2D. RESEARCH DESIGN AND METHODS Fifty individuals with newly diagnosed T2D and 50 age-, sex-, and BMI-matched individuals with NGT underwent liquid mixed-meal tolerance tests to measure glucagon and metabolites, hyperinsulinemic-euglycemic clamps with stable isotope dilution, indirect calorimetry to assess insulin sensitivity and lipid oxidation, and 1H/31P magnetic resonance spectroscopy and MRI to quantify HLC, ATP, and visceral adipose tissue (VAT) volume. RESULTS Individuals with T2D had an ∼65% higher HLC as well as higher fasting and postprandial glucagonemia (∼30% and ∼75%) than those with NGT. Multivariable linear regression analyses revealed that the presence of MASLD, but not T2D, was associated with higher fasting glucagonemia. Interestingly, postprandial glucagon was related to HLC only in T2D, leading to ∼47% higher early postprandial glucagonemia in individuals with combined MASLD and T2D. These differential associations were independent of insulin sensitivity or VAT volume, and neither were mediated by amino acids or NEFAs. CONCLUSIONS Hyperglucagonemia in the face of higher HLC in early T2D is not due to differences in insulin sensitivity or glucagonotropic metabolites but could suggest hepatic glucagon resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany.
- German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany.
- Department of Endocrinology and Diabetology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
- Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany.
- Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, the Netherlands.
- Department of Clinical Biochemistry, Copenhagen University Hospital-Bispebjerg and Frederiksberg Hospital, Bispebjerg, Denmark.
ORCID-Profile: Martin Schön, Nicolai Jacob Wewer Albrechtsen, Patrick Schrauwen, Michael Roden
Förderung
- German Diabetes Society
- German Federal Ministry of Health (BMG)
- Ministry of Culture and Science of the State of North Rhine-Westphalia
- Schmutzler-Stiftung
- Federal Ministry for Research (BMBF)
- German Center for Diabetes Research (DZD)
Zitieren
APA
Huttasch, M., Kahl, S., Mori, T., Heilmann, G., Schön, M., Trenkamp, S., Kupriyanova, Y., Schrauwen-Hinderling, V., Wewer Albrechtsen, N. J., Westhoff, P., Schrauwen, P., Wagner, R., Roden, M., & GDS Group* (2026). Increased Early Postprandial Glucagon Concentrations in Humans With Newly Diagnosed Type 2 Diabetes and Steatotic Liver Disease. Diabetes Care. https://doi.org/10.2337/dc25-3077
Vancouver
Huttasch M, Kahl S, Mori T, Heilmann G, Schön M, Trenkamp S, et al. Increased Early Postprandial Glucagon Concentrations in Humans With Newly Diagnosed Type 2 Diabetes and Steatotic Liver Disease. Diabetes Care. 2026. doi:10.2337/dc25-3077
BibTeX
@article{Huttasch2026,
author = {Huttasch, Maximilian and Kahl, Sabine and Mori, Tim and Heilmann, Geronimo and Schön, Martin and Trenkamp, Sandra and Kupriyanova, Yuliya and Schrauwen-Hinderling, Vera and Wewer Albrechtsen, Nicolai Jacob and Westhoff, Philipp and Schrauwen, Patrick and Wagner, Robert and Roden, Michael and GDS Group*, GDS Group*},
title = {Increased Early Postprandial Glucagon Concentrations in Humans With Newly Diagnosed Type 2 Diabetes and Steatotic Liver Disease},
journal = {Diabetes Care},
year = {2026},
doi = {10.2337/dc25-3077}
}
EUVIMED